Hansa Biopharma Unveils Five-Year Follow-Up Results for Imlifidase in Kidney Transplants at ESOT 2025 Hansa Biopharma showcases exciting five-year data on imlifidase for kidney transplants, demonstrating promising patient outcomes at ESOT 2025 in London.

Hansa Biopharma Unveils Five-Year Follow-Up Results for Imlifidase in Kidney Transplants at ESOT 2025 #Sweden #London #Hansa_Biopharma #imlifidase #ESOT_Congress

Breakthrough in Diabetes Treatment with 3D Printed Human Islets at ESOT 2025 Congress Scientists reveal a revolutionary method for treating type 1 diabetes by 3D printing functional human islets, discussed at the ESOT 2025 congress.

Breakthrough in Diabetes Treatment with 3D Printed Human Islets at ESOT 2025 Congress #USA #London #3D_Printing #diabetes_treatment #ESOT_Congress